Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The endocrine glands of the human foetus are active early in gestation, and various foetal and placental hormonal contributions are essential for growth and sexual differentiation. 1. The anterior pituitary gland has the ability to synthesize, store and secrete hormones early in gestation. The patterns of change in plasma concentrations of hGH (Fig. 1), ACTH, LH and FSH (Fig. 2) during gestation indicate that secretion is at a maximum at mid-gestation, followed by a progressive decrease towards term. The high levels at mid-gestation can be interpreted as due simultaneously to a high secretion rate, low peripheral catabolism and absence of feedback mechanism. In contrast, the secretions of PRL (Fig. 1) and TSH are moderate at mid-gestation and only increase in the last trimester of gestation. 2. Effective control by the central nervous system (CNS) of the pituitary secretions is still immature at mid-gestation. The presence in the foetal hypothalamus of releasing factors such as LRF (Fig. 5) and TRF, and of somatostatin (Fig. 6), a growth hormone release inhibiting factor (GIF), has been established. TRF and GIF, but not LRF, are also present in the cerebral cortex. It has been postulated that, early in life, relatively autonomous and unrestrained secretion of hypothalamic hypophysiotropic releasing factors occurs, and that, later in development, there is a maturation of inhibitory or restraining influences mediated via the CNS (feedback mechanisms) that modulates the secretion of the foetal adenohypophyseal hormones (Fig. 3 and 4). 3. Observations made with anencephalic newborn confirm that a functional hypothalamus is necessary during foetal life for the secretion of each of the hormones of the anterior pituitary gland with the exception of PRL, the secretion of which is normal in anencephaly. Although somatostatin probably participates in the regulation of hGH during foetal life, it appears evident from the anencephaly data that this regulation can only be fully understood by postulating the existence of a growth hormone releasing factor (GRF).
 ...
PMID:[Ontogenesis of hypothalamic control of adenohypophyseal secretions in the human foetus (author's transl)]. 11 47

The anterior pituitary gland of the human fetus has the ability of synthetizing, storing and secreting hormones early during gestation. The patterns of plasma concentrations of hGH, ACTH, LH and FSH during gestation indicate a maximum of secretion at mid-gestation followed by a progressive decrease of these concentrations until term. In contrast, the secretions of PRL and TSH are moderate at mid-gestation and only increase in the last trimester of gestation. Effective control by the central nervous system (CNS) of the pituitary secretions is still immature at mid-gestation. The presence of releasing factors in the fetal hypothalamus has been established (TRF, LRF, somatostatine) and it was postulated that early in life, relatively autonomous and unrestrained secretion of hypothalamic hypophysiotropic releasing factors occurs and, later in development, there was a maturation of inhibitory or restraining influences mediated via the CNS that modulate the secretion of the fetal adenohypophyseal hormones. Observations made with anencephalic newborns confirm that a functional hypothalamus is necessary for the secretions of each of the hormones of the anterior pituitary gland with the exceptiion of PRL, the secretion of which is normal in anencephaly. Although somatostatin probably participates in the regulation of hGH during fetal life, it appears evident that this regulation can only be fully understood with the existence of a GRF (Growth Hormone Releasing Factor).
 ...
PMID:[Hypothalamic factors in the human fetal brain: their role in the ontogeny of fetal hypophyseal functions]. 20 94

Radioimmunoassays of brain extracts have shown that several peptides occur in high concentrations in the CNS. The releasing-factor peptides TRF, LRF, somatostatin, CRF and GRF have the highest concentration in the hypothalamic extracts. High levels of somatostatin, CCK octapeptide, neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) are found in cortical extracts. Substance P, CCK, NPY, and enkephalins are present in high concentrations in basal ganglia and mesolimbic areas. Pharmacological doses of these peptides result in several behavioural and vegetative effects. Immunocytochemical studies show that the CNS peptides are localised in neurones and in synaptic vesicles. In vitro studies with brain tissues show that peptides are capable of modifying the ongoing classical neurotransmission. In depressive patients several neuropeptides (CCK, CRF and NPY) have been shown to have low CSF levels. Patients dying of senile dementia have low cortical levels of somatostatin, CRF and substance P. In schizophrenic patients CCK peptides have shown to improve some symptoms. At present the therapeutic potentials of peptides are poorly known. More studies are required to understand their role in neurotransmission and related pathological states.
 ...
PMID:Peptides and neurotransmission in the central nervous system. 282 29

With the aid of light- and electron- microscopic immunocytochemistry, somatostatin- and luliberin (LRF)-positive fibers can be demonstrated in the rat subfornical organ (SFO). Each of the neurohormones has a specific location: LRF in the lateral parts of the organ, and somatostatin in the center of the posterior zone. Common to both neurohormone-containing fibers is the pattern in which they reach the organ as well as the fact that their terminals are located in the perivascular spaces of fenestrated vessels, i.e., within the limited neurohemal regions of the organ. Since injection of India ink of different colors demonstrates that the capillary bed of the SFO is connected with the central capillaries of the choroid plexus, the question arises as to whether the neurohormones released in the area of the SFO influence the choroid plexus.
 ...
PMID:Luliberin and somatostatin fiber-terminals in the subfornical organ of the rat. 610 22

With the aid of electron microscopic immunocytochemistry following the application of antisera against somatostatin and luliberin (LRF), a labeling of the intercellular clefts in different areas of the brain was observed. This labeling is especially conspicuous near the basal pose of the cuboidal ependymal cells, but is also generally present in all regions containing neurohormone-producing perikarya or their processes (for example, the preoptic area, the basal ganglia and the cortex). Furthermore, in all these regions displaying labeled intercellular clefts, glia-like cells and sparsely ciliated ependymal cells are found, the secondary lysosomes of which exhibit an immunoreactivity resembling that observed in the intercellular clefts. As sources of the immunoreactive material the following possibilities are discussed: (i) perikarya producing somatostatin or LRF, situated in the wall of the third ventricle and sending fibers between the cuboidal ependymal cells, (ii) hypothalamic and extrahypothalamic projections of both peptidergic systems, and (iii) in the case of somatostatin, immunoreactive perikarya in the cortex.
 ...
PMID:Neurohormones in the intercellular clefts and in glia-like cells of the rat brain. 610 30

By means of light-microscopic immunohistochemistry the perikarya of the luliberin-(LRF-) and somatostatin systems of neonate rats were found to be in differing stages of development. At a time point when the LRF-producing neurons had obviously attained their final shape and size, the somatostatin-immunoreactive perikarya were still in a postnatal phase of maturation. Whereas the number of the latter perikarya increases with advancing age, the number of LRF-immunoreactive perikarya decreases significantly from postnatal day 7 onward. Both peptide-hormone systems do not project concomitantly and to the same extent to their principal neurohemal regions in the organum vasculosum laminae terminalis (OVLT) and the median eminence (ME). In all presently studied stages of development, despite considerable individual variations in one age group, among the components of the LRF-system the OVLT displays a more intense immunoreactivity than the ME. The somatostatin system, however, projects to the OVLT with a conspicuous temporal delay compared to the ME, and, furthermore, in the OVLT the pattern of immunoreactivity characteristic of adult rats is not yet attained at postnatal day 21. Evidence for differences in the immunoreactivity between male and female animals was restricted to the LRF-system. Finally, the results obtained on the stria terminalis speak in favour of the fact that the long-range extrahypothalamic projections of the somatostatin system also undergo postnatal maturation. In the stria terminalis, somatostatin-immunoreactive fibers can be demonstrated initially on postnatal day 7. They attain their full immunoreactivity on postnatal day 21. Furthermore, in the bed nucleus of the stria terminalis an intermittent cytoplasmic immunoreactivity is observed, which is limited to the animals of postnatal day 7 and disappears completely during the further course of development.
 ...
PMID:Differing postnatal development of the somatostatin- and luliberin- systems in the male and female rat. 613 32

Tryptophan is readily oxidized to oxindolylalanine (2-hydroxytryptophan) in good yield on treatment in acetic acid solution with a mixture of dimethyl sulfoxide (DMSO) and concentrated aqueous HCl at room temperature. Other sulfoxides can be used in combination with HCl; for example, methionine sulfoxide reacts with an equimolar amount of tryptophan to give high yields of methionine and oxindolylalanine. Methionine and cysteine are quantitatively oxidized by DMSO/HCl to methionine sulfoxide and cystine, respectively. The tryptophan containing peptides LRF (luteinizing hormone-releasing factor), somatostatin, valine-gramicidin A and ACTH 1-24 were each treated with the DMSO/HCl reagent in acetic acid solution and the corresponding oxindolylalanine-derivatives isolated in over 90% yield after chromatography. The identity and purity of the derivatives were established on the basis of ultraviolet spectral characteristics and quantitative amino acid analysis of the oxindolylalanine content of acid hydrolyzates of the oxidized peptides with 3N-p-toluenesulfonic acid at 110 degrees for 24 h. The results indicate that modification of tryptophan peptides with DMSO/HCl provides a useful procedure, which seems superior to previously used reagents. In addition, the method could be well applied to other indoles of biological and pharmacological interest.
 ...
PMID:Oxidation of tryptophan to oxindolylalanine by dimethyl sulfoxide-hydrochloric acid. Selective modification of tryptophan containing peptides. 615 58